Patient access to biologic therapies is an issue throughout the European Union where the authors of a review article zero in on “why.” Access issues, they find, have a lot in common with access issues here in the U.S.
Gregory M. Weiss, M.D.
Rheumatoid arthritis, psoriasis and psoriatic arthritis patients have consistently low levels of biologic adherence and persistence. How can patient compliance be improved? Lower out-of-pocket costs, utilize specialty pharmacies and improve patient education.
Delays in diagnosing axSpA are troubling, write the authors of a report in the journal Rheumatology. Delays of up to 10 years have been reported. Not all physicians may be familiar with the signs and symptoms of axSpA.
Physiotherapy, exercise and pain medications should be part of the treatment plan to improve the quality of life of patients suffering from stiffness associated with axial spondyloarthritis.
A new study published online ahead of print in Arthritis Care & Research sheds light on the barriers rheumatology patients face with regards to smoking cessation while describing individual reactions to cessation protocols and identifying patient centered outcomes after improvements in care.
Increased competition in the pharmaceutical market does not necessarily translate into price reductions. "Our findings illustrate a market failure contributing to the rising costs of prescription drugs," researchers write in JAMA Internal Medicine.
Using a frailty index to predict adverse outcomes and mortality in systemic lupus erythematosus proves to be feasible and effective in a study. The test, SLICC-FI, correlated well with existing measures of SLE disease activity, organ damage and HRQoL.
A recent study published in Arthritis & Rheumatology has demonstrated that belimumab is both safe and effective in patients with systemic lupus erythematosus and provides disease control over the long term.
A recent study published in the Annals of the Rheumatic Diseases shows that ankylosing spondylitis is linked to an increased risk for venous thromboembolism and deep vein thrombosis.
Smoking in axial spondyloarthritis doesn't appear to impact treatment with TNF inhibitors despite the status of disease severity, a study shows.